| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-11-18 | Qiagen (The Netherlands) Eli Lilly (USA) | companion diagnostics | development |
Cancer - Oncology | Development agreement | |
| 2013-11-18 | Silence Therapeutics (UK) | nomination resignation |
Nomination | |||
| 2013-11-12 | Helsinn (Switzerland) Chugai Pharmaceutical (Japan) | anamorelin | anorexia-cachexia | distribution |
Cancer - Oncology | Commercialisation agreement |
| 2013-11-12 | Nicox (France) Sjögren’s Syndrome Foundation | Sjögren’s Syndrome | Ophtalmological diseases - Rare diseases | Collaboration agreement | ||
| 2013-11-12 | Biofocus, a Galapagos Company (UK - Belgium) BiogenIdec (USA -MA) | novel targets in scleroderma | scleroderma | Autoimmune diseases | Collaboration agreement | |
| 2013-11-08 | ImmunID (France) | nomination |
Diagnostic - Cancer - Oncology | Nomination | ||
| 2013-11-06 | Orexigen Therapeutics (USA) Sanofi (France) | Contrave® (32 mg naltrexone sustained release (SR) / 360 mg bupropion SR) | obesity, including weight loss and maintenance of weight loss, in conjunction with lifestyle modification | manufacturing |
Metabolic diseases | Production agreement |
| 2013-11-05 | Evotec (Germany) The Leukemia & Lymphoma Society (USA) | R&D |
Cancer - Oncology | R&D agreement | ||
| 2013-11-05 | Summit (UK) Joining Jack (UK) | novel biomarkers for Duchenne Muscular Dystrophy (DMD) | R&D |
Neuromuscular diseases - Rare diseases | R&D agreement | |
| 2013-11-05 | Novo Nordisk (Denmark) Oxford University (UK) | international fellowship programme | diabetes | collaboration |
Metabolic diseases | Collaboration agreement |
| 2013-11-05 | Pathoquest (France) Covance (USA) | Next-Generation Sequencing (NGS) based biosafety assessments | collaboration |
Technology - Services | Collaboration agreement | |
| 2013-11-05 | ADC Therapeutics (Switzerland) Five Prime Therapeutics (USA) | human antibodies directed to an undisclosed target expressed on the surface of various types of cancers | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-11-04 | Addex Therapeutics (Switzerland) National Institute on Drug Abuse (NIDA) (USA) | ADX71441, ADX88178 | drug abuse, addiction | collaboration |
CNS diseases | Collaboration agreement |
| 2013-11-04 | Roche (Switzerland) Polyphor (Switzerland) | POL7080 | infections caused by Pseudomonas aeruginosa | development |
Infectious diseases | Development agreement |
| 2013-11-04 | Cancer Research Technology (UK) Nuevolution (Denmark) | anti-cancer drug molecules targeting several key proteins | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-11-04 | 4SC Discovery (Germany) AiCuris (Germany) CRELUX (Germany) | small molecule compounds targeting pathogen-specific interactions in infectious diseases | R&D |
Infectious diseases | R&D agreement | |
| 2013-11-04 | CureVac (Germany) Cancer Research Institute (USA) Ludwig Cancer Research (USA) | CV9202 | development |
Cancer - Oncology | Clinical research agreement | |
| 2013-11-04 | Merck Serono (Germany) Kadimastem (Israel) | drug screening assays using stem cell-derived astrocytes | multiple sclerosis | R&D |
Neurodegenerative diseases | R&D agreement |
| 2013-11-04 | AstraZeneca (UK) Agency for Science, Technology and Research (A*STAR) (Singapore) | new drugs to treat Gram-negative bacterial infections | Gram-negative bacterial infections | R&D |
Infectious diseases | R&D agreement |
| 2013-10-31 | Lundbeck (Denmark) Otsuka Pharmaceutical (Japan) | up to five innovative psychiatric and neuroscience products including aripiprazole depot formulation, OPC-34712 | R&D |
CNS diseases | Development agreement |
